Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Pituitary Neoplasms 7Acromegaly 4Prostatic Neoplasms 3Carcinoid Tumor 3Pituitary ACTH Hypersecretion 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Thyroid Neoplasms 1Serotonin Syndrome 1Prolactinoma 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Nelson Syndrome 1Myelodysplastic Syndromes 1Meningioma 1Melanoma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1

Interventions

Cyclophosphamide 130Methotrexate 93fludarabine phosphate 74Cytarabine 71Vincristine 66Whole-Body Irradiation 65Mycophenolic Acid 58Dexamethasone 55Tacrolimus 49Peripheral Blood Stem Cell Transplantation 48fludarabine 47Busulfan 46pegaspargase 43Filgrastim 41Etoposide 41Doxorubicin 41Calcium Dobesilate 40Granulocyte Colony-Stimulating Factor 39Rituximab 36Cyclosporine 36Mercaptopurine 35Melphalan 33Prednisone 31merphos 28Clofarabine 26Asparaginase 26Antilymphocyte Serum 25Leucovorin 23Daunorubicin 23Thiotepa 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor Cell Lymphoblastic Leukemia-Lymphoma × pasireotide × Clear all
NCT02215070 2021-11-17

Pasireotide in Prevention of GI Toxicity

Duke University

Phase 2 Completed
37 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡